Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

Coronary Microvascular Dysfunction: Pathophysiology, Diagnosis, and Emerging Clinical Strategies

Harshita Sain[1], Aparna Manoj M[1] , Dikshant Bishnoi[*1]

[1]Department of Paramedical Sciences, NIMS University

[1]School of Health Science, Om Sterling Global University

[*1]School of Allied Health Science, Jaipur National University

(Received: 27 September 2025 Revised: 05 October 2025 Accepted: 10 November 2025)

KEYWORDS

Coronary Microvascular Dysfunction, Small Vessel Disease, Microvascular Ischemia, Non-Obstructive Coronary Artery Disease, Endothelial Dysfunction

ABSTRACT:

Coronary Microvascular Disease (CMD) as well as Small Vessel Disease (SVD) are recognized for myocardial ischemia, mostly In patient with angina. In recent time diagnosis of obstructive CAD via cardiac catheterization and visualizing the epicardial vessel became a gold standard method and the prognosis changed into importantly constrained to large vessels commonly without detection of abnormalities in the coronary microcirculation but it leaves big number of sufferers with ischemia undiagnosed. CMD and SVD represent a spectrum of functional and structural alterations in coronary microvasculature, manifested as defective vasodilatory response, endothelial dysfunction, inflammation, and small vessel rarefaction resulting in compromised myocardial perfusion. The etiology of CMD and SVD are multifactorial. Endothelial dysfunction and oxidative strain and inflammation disrupt finely tuned regulation of vascular tone but structural remodelling of even the arterioles can reduce perfusion to the heart by reduction in capillary density. These microvascular abnormalities frequently are associated with conventional cardiovascular risk components in addition to high blood pressure, diabetes mellitus, and dyslipidaemia; but they can also seem in the absence of simple danger elements on occasion as unmarried phenomenon broadening the understanding of their complicated etiology.

Novel non-invasive imaging technologies that have revolutionized the assessment of CMD and SVD have been classified together with invasive pressure echocardiography; cardiac magnetic resonance (CMR) imaging with perfusion mapping; and positron emission tomography for the assessment of myocardial blood flow, coronary flow reserve or microvascular function [all representing functional as opposed to anatomical image] as the latest generation of testing. These possess high sensitivity and specificity in the identification of microvascular ischemia, with their top achievements being risk stratification as well as selection of healing and evaluation of therapy efficacy. Invasive methods such as intracoronary Doppler flow volume and thermodilution technique for volume resolution are also good methods to show coronary anatomy in the given patient. CMD/SVD Proper knowledge of diagnosis and therapy. Patients with diffuse microvascular disorder have a significantly prolonged risk of adverse cardiovascular events, such as heart failure with preserved ejection fraction, recurrent angina, and myocardial infarction without or with severe epicardial stenosis. The current treatment consists of management of behavioral risk factors and a combination of optimal antianginal therapy together with pharmacological agents that target the endothelium and microvasculature (statins, ACE-inhibitors, beta-blockers), in addition to the new vasodilatory substances. Diagnosing these types of patients could be better if the molecular mechanisms and new healing marketers were researched.

This assessment extensively critiques the area of CMD and SVD, highlighting knowledge gathering through both invasive and non-invasive diagnostic methods; understanding pathophysiology and clinical implications. In that scenario, a definite part of the game would be, early personalized and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

targeted therapy as well as the protracted cardiac outcome with the successful identification of coronary microvascular disease without diagnostic delay. The review is intended to throw current tendencies in imaging and treatment, thus elevating the interest of the teaching clinicians, bench researchers and payees around the changing microvascular coronary disease landscape and its present-day scientific cardiology relevance.

1. Introduction

Studies have shown that coronary artery disease (CAD) plays a leading cause of morbidity and mortality worldwide. Also, diagnosis and therapy were previously geared towards obstructive epicardial coronary artery stenosis (1). However, there are a number of patients with angina or ischemic symptoms who do not have obstructive lesions on coronary angiography, implying that coronary microvascular dysfunction (CMD) and small vessel disease (SVD) are important pathophysiological components in causing ischemic heart disease (2). Coronary microvascular dysfunction is defined as impaired flow regulation through the visualized small arterioles and capillaries of the coronary circulation based on an abnormal vasodilatory response, increased microvascular resistance, or impaired endothelial and smooth muscle function. Small vessel disease is typically synonymous with CMD and refers to the involvement of these intramural coronary vessels which fail to provide adequate myocardial perfusion in the absence of epicardial stenosis(3). Taken together, CMD and SVD have become increasingly recognized as important contributors to ischemia without obstructive coronary artery disease (INOCA), which has previously been undervalued and undertreated (4).

CMD and SVD are significantly the causes of mismatch in myocardial oxygen demand and supply leading to angina, dyspnoea, and poor functioning in sick patients. Such states aren't benign, and there may be collecting evidence that sufferers with CMD or SVD are at excessive danger for adverse cardiovascular outcomes which include recurrent hospitalizations, major destructive cardiac occasions (MACE), HFpEF, and a terrible high-quality of existence [5]. Indeed, CMD has emerged as an essential mechanism of INOCA and maximum recently is seemed as a wonderful entity with its diagnostic and prognostic implications. These unmet dreams to symbolize microvascular disorders on the grounds of, as traditional angiography points out, now additionally newer diagnostic methods come to be increasingly more "en trend" into the catheterization laboratory like: coronary float reserve (CFR), index of microcirculatory resistance (IMR) and acetylcholine everything provocative checks make in the end addressable a simultaneous endothelial popularity and microvasular cramp. Three: Epidemiology The epidemiological figures are illuminated (CMD and SVD are sizeable and regularly continue to be undiagnosed. In about forty-50% of sufferers who have a CA on the premise of anginal symptoms, there is no evidence for obstructive CAD and turns out that a subset has CMD (6). It is similarly located that there's a disproportionally excessive female preponderance Women's Ischemia Syndrome Evaluation and others record an unjust burden of microvascular angina among women. It has been counseled that hormonal effects, accelerated small vessel size and varying endothelial reactivity all play a role inside the greater common incidence in girls. CMD is also had by those with other classic cardiovascular risk factors such as hypertension, diabetes mellitus, dyslipidaemia, or obesity, and chronic inflammatory conditions cause endothelial dysfunction as well as structural remodelling of the microvasculature (7). CMD is currently also being recognized as a vital linchpin linking systemic diseases, such as autoimmune disorders and chronic kidney disease, and thus elevates its clinical significance beyond classical coronary pathology (8).

The main clinical aspect of CMD (Coronary microvascular disease) (1) is associated with the long-term prognosis only.CMD patients find themselves in the situation where they are repeatedly suffering from angina and are re-admitted to the hospital, they have limited exercise capacity and remain in a bad condition. Essentially, this means massive amounts of health care usage and economic load (9). It appears that CMD is not an abnormality with a short and fast disappearing pattern anymore; long-term studies have acknowledged it as atherogenic and as growing the risk of major adverse cardiovascular events (MACE), such as MI, stroke, and cardiovascular death (10).

True, CMD is the initial substratum of HFpEF, diastolic disorder with very limited treatment procedures, hence the systemic and revolutionary properties featured in microvascular disease coexisting with CMD are emphasized. Though being of significant clinical value, CMD can be ignored in half of the cases, where no angiographically defined obstruction is found—thus it is termed ‘no obstructive coronary artery disease’ or a

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

historic bias against the microvasculature (11).These missed diagnosis causes late selection of treatment and suboptimal management of a high percentage of patients that continue to have ischemic symptomatology irrespective of no obstructive coronary disease (12).

2 Pathophysiology and Clinical Presentation

2.1 Pathophysiology

Consequently, CMD and SVD feature interiliac that is the underpinning mechanistic aspect to reducing blood supply to the myocardium in both the structural and functional aspect of coronary microcirculation. In structural terms, the above-mentioned remodelling is capillary and arteriolar rarefaction, wall thickening of arterioles, perivascular fibrosis, and hyperplasia of smooth muscle in hypertension, diabetes mellitus, dyslipidaemia, and inflammation when exposed to the confounding cardiovascular risk factor (13). A decrease in the diameter creates resistance to flow in capillaries and limits flow to the coronary artery. Functionally, the most important aspect of CMD is endothelial dysfunction in many cases. There are vasodilators such as nitric oxide and prostacyclin synthesized from the endothelial cells for the maintenance of vessel tone; however, in CMD conditions will compromise this capacity for vasodilation due to oxidative stress and inflammatory mediators (15). As a result, a smooth muscle hyperreactivity modifies the further balance through hyperactivation of vasoconstrictor pathways. Altogether, this deranged system impairs coronary flow reserve (CFR), which is the maximum obtainable blood flow over resting blood flow in the ratio. The fact that the CFR tends to be low indicates that the coronary circulation cannot sufficiently perfuse the myocardium to satisfy oxygen demand during stress on exertion; hence the onset of ischemia without lesions in angiographically normal epicardial vessels (16).

2.2 Clinical Presentation

The imbalances between oxygen supply and demand result in the causes of most clinical manifestations associated with CMD and SVD, with chest pain being the most common symptom, occurring either on exertion or at rest, and often confused with that due to obstructive coronary artery disease. Other manifestations include dyspnoea, tiredness, palpitations, and exercise intolerance. CMD is indeed well associated with ischemic symptomatology and nonobstructive coronary artery disease (INOCA), where patients report episodes of angina despite angiography showing clean or almost-clean epicardial arteries. Symptoms in CMD tend to be less predictable than those of obstructive disease, being generalized, prolonged, or atypical. Besides these well-recognized atypical presentations, which pose diagnostic challenge, women may also experience epigastric discomfort or back pain and associated shortness of breath(20).

2.3 Diagnostic Challenges

What about CMD? It might be the most difficult thing to solve/ the worst task to handle. Coronary angiography just shows the epicardial vessels and this is not enough to explain the small changes that are the reason for normal results alongside with the relevant symptoms. Because of this, some patients who actually experienced a SYMP may find themselves with poor ECG results or a different diagnosis like stress or musculoskeletal pain. Besides that, the angina connected to CMD can be nitrate-resistant, which makes the diagnosis more confusing. Microvascular disorder can only be determined through an invasive cath lab method with coronary flow reserve, index of microcirculatory resistance (IMR), and acetylcholine provocation testing (21). These tests confirm the disorder of the endothelium and smooth muscles and help to detect CMD in patients with INOCA. However, in reality, these tests are seldom done, therefore, a large number of people are misdiagnosed and untreated. This diagnostic gap indicates the need for increased awareness and proper screening of CMD in the clinical setting (22).

3. Role of Cath Lab in CMD/SVD Detection

The cath lab continues to perform a major role in the history of diagnostic invasive procedures for obstructive coronary artery disease (CAD) as it allows direct visualization of the epicardial vessels; hence coronary angiography became the standard method for the evaluation of the anatomy and for deciding on which lesions to treat by using percutaneous coronary intervention (PCI)(23). The acknowledgment of coronary microvascular dysfunction (CMD) and small vessel disease (SVD) as primary sources of the disease process in the ischemic syndromes has underlined the extent of their involvement beyond the anatomical issues (24).

CMD and SVD can negatively impact myocardial ischemia, that is, they can cause myocardial ischemia in such a way that no obstruction of epicardial lesions is visible - a condition which, unfortunately, can by far receive the least attention from most (24). Non-invasive imaging stress echocardiography, cardiac magnetic resonance (CMR), and 13N-ammonia positron emission tomography (PET) provide the necessary ground for the explanation of myocardial perfusion and ischemia (25). These are very good and correctly used modalities for the initial assessment; however, it seems that sometimes they

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

trade accuracy for reproducibility and even have some problem differentiating among epicardial and microvascular causes of ischemia (26). Cath lab gets a real-time and high-fidelity procedure of coronary body structure that allows for the accurate interrogation of both epicardial and microvascular vessels (27).

One of the invasive methods is to know the coronary flow reserve (CFR) as well as the index of microcirculatory resistance (IMR) and endothelial characteristics through acetylcholine or adenosine provocation. With this mechanism, it is quite feasible to recognize an abnormal vasodilation, microvascular spasm, or increased microvascular resistance, which remain non-recognized by the widespread angiography (28). Invasive tests will offer more particular diagnostics and a patient-focused treatment for CMD and SVD by locating the particular mechanism of ischemia. For example, the rise in IMR or low CFR might suggest the add-on of antianginal therapy while the endothelial dysfunction determined by acetylcholine can be considered treatment with calcium antagonists, nitrates, or lifestyle change (29).

An benefit of invasive exams is the possibility of tremendous physiological evaluation simultaneously with angiography on the identical consultation. This expedites diagnosis and stops duplication of processes and waiting time for affected person control (30). For those sufferers who've Ischemia with No Obstructive Coronary Artery Disease (INOCA), the cath lab converts an "harmless" angiogram into a useful medical device that gives signs validity and centered control (31).

3.1 Recommended Guidelines for Invasive Testing

International cardiovascular societies advise the necessity of invasive tests for CMD and SVD in patients presenting with angina and unobstructed epicardial arteries. According to the 2019 European Society of Cardiology (ESC) hints-in principle, they recommend the initiation of invasive functional evaluation in continual symptomatic patients for whom there may be suspicion of ischemia (32). Among these specific proposals might be measuring coronary glide reserve and index of microvascular resistance via invasive practical evaluation and testing an endothelial disorder and/or microvascular or epicardial spasm caused by using an administration of acetylcholine, which it deems essential to assess. These are class IIa hints, which means that proof exists of their Favor regarding the diagnostic accuracy and chance stratification (33). Holding CMD consists of therapeutic implications due to the fact CMDs tend to be related to an improved chance for recurrent anginas, improved hospitalizations, and major destructive cardiovascular occasions (MACE). Thus, on noting the presence of microvascular disorder, it empowers clinicians to initiate the channelled focused on of therapies, optimize danger component management, and supply prognostic advice (34).

The recommendations of the AHA/ACC similarly extend beyond the standard ESC guidelines in regard to who must be invasively examined in positive populations, particularly girls, who're disproportionately affected by INOCA and CMD. These two societies advocated for the inclusion of invasive coronary physiology testing into trendy practice within tertiary centres with superior Cath lab facilities. Of extreme importance is that the guidelines emphasize the want for individualized diagnosis: not every affected person wishes invasive checking out, but people with recurrent angina and inconclusive non-invasive exams or suspected microvascular ailment ought to be taken into consideration for cath lab evaluation.

3.2 Clinical Relevance and Future Perspectives

The protocols of CMD and SVD invasive checking out, as in most important adjustments, are being carried out to the evaluation of ischemic coronary heart disease. Traditionally, cath labs were considered most effective to rule out obstructive CAD, whereas now-comparatively greater currently- cath labs have extra emerged as a diagnostic domain for INOCA patients, granting capacity pathophysiological insights not possibly afforded by non-invasive imaging (36). Thus, by way of identifying the mechanisms of ischemia, invasive assessments can then better consciousness control techniques, which- as an example- can involve improved antianginal therapy, modulation of endothelial dysfunction, or greater competitive manage of threat elements (37).

In simple terms, CMD has been shown to be associated with those cases which return with symptoms like angina, heart failure, and cardiovascular death in a long period of time. Symptom relief, fate risk estimation, and long fluxuation management supply all the strong clinical sign and justification for the examination done by invasive testing. Besides this, an invasive evaluation enables the follow-up of therapeutic reaction with objective endpoints related to pharmacological intervention and life-style modulation (38). Newer methodologies are predicted to provide easy access and precision in the usage; for example, IMR (aIMR) from angiography and continuous drift measurement systems can have less procedural complexity and operator dependence. Along with non-invasive imaging such as CMR or PET, it seems that traditional invasive hemodynamic criteria would offer a hybrid diagnostic scheme that would enhance danger stratification and therapeutic planning. The function of the cath lab will continue to grow as we reach greater cognizance of CMD/SVD and undertake further in addition advice (39).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

The number of patients that would benefit from early detection and treatment is going to increase, in that they could then avoid undiagnosed ischemia, better quality of life, and decreasing healthcare costs related to recurrent hospitalizations and unnecessary procedures. The cath lab is no longer the exclusion only for obstructive CAD but is now playing a main role in precision diagnosis and control for INOCA patients and is redefining the entire concept of ischemic heart disease (40).

4. **Invasive Diagnostic Techniques and Indices**

4.1 Coronary Flow Reserve (CFR)

Coronary Flow Reserve (CFR) is an invasive index that has been thoroughly validated and clinically selected to measure coronary microvascular function. It represents the ability of the coronary circulation to increase blood flow over a base level in response to some stress, most often hyperaemia induced by pharmacological means. Theoretically, the definitions of CFR relate to the hyperaemic value of coronary blood flow divided by the resting coronary blood flow, thereby integrating both epicardial and microvascular contributions to coronary perfusion (41). Either Doppler flow velocity or thermodilution methods, usually performed on adenosine hyperaemia, can be used to take the measurements; the hyperaemia maximizes vasodilation. Values for CFR below 2.0-2.5 are generally considered to be abnormal, suggesting impaired microvascular function. Studies have consistently linked reduced CFR to adverse clinical outcomes like recurrent angina, exercise intolerance, heart failure, and an increase in major adverse cardiovascular events (MACE) (42). Even though there is much overlap as far as clinical presentation is concerned, CFR is influenced by both epicardial coronary stenosis and microvascular dysfunction, which may compromise specificity of the marker toward microvascular abnormalities. Heart rate, systemic blood pressure, left ventricular hypertrophy, and the technical variability encountered during measurement can also affect reproducibility. Thus, evaluation alongside IMR provides better specificity in assessment of microvascular performance (43). However, due to the extensive validation, ease of implementation, and integrated measure of perfusion dynamics over the coronary tree, it is regarded as the most important index in CMD evaluation by invasive techniques. Besides prognostic insights with respect to symptom assessment, longitudinal studies have also developed CFR, reduced for cardiovascular events risk, independent of traditional risk factors or epicardial stenoses. Therefore, beyond being a diagnostic parameter, CFR is also an important parameter for risk stratification of patients with ischemia and no obstructive coronary artery disease. CFR will even provide feedback in real-time in assessing the impact of therapeutic interventions-pharmacological agents, revascularization procedures, or lifestyle intervention-by recording the longitudinal measure of microvascular responsiveness (44).

4.2 Index of Microvascular Resistance (IMR)

The Index of Microvascular Resistance (IMR) is an invasive index that can assess microcirculation and is independent of epicardial disease. IMR is calculated by multiplying distal coronary pressure with mean transit time of bolus saline during maximal hyperaemia induced by adenosine (45). While CFR solely measures epicardial stenosis, the IMR seriously considers the fact that it measures microvascular function, which is quite less influenced by systemic hemodynamic fluctuations. An IMR value ≥25 is commonly regarded as diagnostic for CMD; IMR values ≥40 indicate more severe microvascular disease, which is more prognostically significant. Among IMR advantages, some probably include: It can be repeated and is not lesion-dependent and is less affected than CFR by varying influences of heart rate, blood pressure, or left ventricular function (46). On this basis, IMR has proved it's worth to become a preferred tool in Cath labs to objectively assess microvascular insufficiency for use in modern management of patients. Aside from being a diagnostic index, IMR permits CMD to be classified into different sub phenotypes, with treatment effects anticipated (47). A potential increase in IMR with the absence of epicardial obstruction could be either an intensification of medication treatments, such as beta-blockers, ACE inhibitors, or vasodilators, or may involve more vigilant follow-up status for poor cardiovascular outcomes. IMR has been revealed to predict more than symptomatic burden in the time-to-event analysis (48). Several multicenter registries correlate that high IMR values relate to recurrent angina, heart failure admission, and increased myocardial infarction and cardiovascular mortality risk. This indicates a role for implementing IMR in daily practice for the evaluations of patients with INOCA, when non-invasive imaging is unable to demonstrate characteristic ischemic patterns (49).

4.3 Hyperaemic Microvascular Resistance (hMR)

Hyperaemic microvascular resistance represents another invasive measure of coronary microvascular resistance derived from inducing pharmacologically hyperaemia and measuring coronary flow with Doppler-based techniques. It is a measure of microvascular resistance under induced stress conditions and is calculated by the division of distal coronary pressure by hyperaemic flow velocity; thus, a value greater than 2.5 mmHg/cm/s is usually deemed abnormal in respect of impaired microvascular function (50).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

Conceptually, hMR is like IMR; however, it is more dependent on the technology of Doppler wire and operator expertise, which has limited its adoption for widespread clinical use. In general, hMR does provide some complementary information about the functional state of the coronary microcirculation, especially in investigational or specialized clinical practice. For instance, the hMR measures resistance under hyperaemic conditions independently and enhances the interpretation of microvascular function, potentially being of value in borderline and complex cases that others like IMR or CFR alone may not resolve as cases of microvascular dysfunction(51).

4.4 Angiography-Derived IMR (aIMR)

With the development of a few recent advances in computational imaging schemes, a new angiography-derived IMR (aIMR) has been introduced. This non-wire, angiogram-based approach estimates microvascular resistance. With the help of this technique, normal coronary angiographic images are complemented with flow and pressure modelling via computation to obtain an indirect estimation of microvascular functionality. The use of aIMR simplifies the procedure by relieving the operator of using pressure or flow wires, shortening overall procedural time, and reducing operator dependency. A number of early validation studies have shown a high degree of concordance of aIMR with IMR measured traditionally with wires. This suggests that aIMR stands a good chance of becoming a rapid and readily available means of measuring microvascular resistance with utility in day-to-day clinical practice. Since it is a non-invasive technique, it also becomes very suitable for patients at high procedural risk or unable to tolerate hyperaemic agents. However, once again, aIMR represents a platform technology, and its utility for investigations would only be determined following large-scale validation trials before being brought into routine clinical decision-making by then. However, this represents new avenues through which microvascular assessment can be carried beyond specialty centers into the general population.

4.5 Continuous Thermodilution and Quantitative Techniques

Continuously, a number of the traditional bolus thermodilution strategies were then used, which actually have become non-stop thermodilution for offering absolute quantification of both coronary waft and coronary resistance. The continuous infusion of an isotonic saline answer at room temperature by a dedicated catheter allows computation of absolute coronary glide (Q) and microvascular resistance (Rμ) (55). Simply put, non-stop thermodilution has removed operator dependence, expanded reproducibility, and the possibility for organising an absolute rather than a relative evaluation of coronary body structure. This qualitative development of the approach over absolute go with the flow and resistance measurement affords diagnostic accuracy, longitudinal comply with-up, and treatment reaction benchmarks. Although still sluggish to take hold in clinical exercise, it promises to end up a part of recurring cath lab protocols, specially for complicated or excessive-hazard patients whose microvascular characteristic is quantification important (56).

4.6 Endothelial Function Testing

For CMD, the pathophysiological aspect is endothelial dysfunction; as a result, an invasive assessing method to study this situation is the acetylcholine assignment check. Acetylcholine is injected into the coronary arteries in increasing doses on the way to degree the vasodilatory capability. Healthy endothelium could bring about vasodilation through the vasodilator acetylcholine; in contrast, dysfunctional vessels develop vasoconstriction or spasm(fifty-seven). The expertise of the endotype could for that reason inform the remedy strategy: calcium-channel blockers and nitrates may help pry open sufferers suffering from vasospastic angina, whilst beta-blockers, ACE-inhibitors, and a few corridor anti-anginal sellers will likely cope with structural microvascular disorder(fifty-eight). Endothelium trying out along with different invasive indices thus offers the clinician a complete physiological profile of the CMD, allowing customized remedy with an outlook for stepped forward scientific outcomes (59).

4.7 Other Indices (MRR, RRR)

Sequel novel indices were created initially to fine-tune the first-class grading of the characteristics of the microvascular. Microvascular Resistance Reserve (MRR) indicates the potential of microcirculation to lower the baseline resistance as compared to the level that would be under hyperemia; the Resistive Reserve Ratio (RRR) which is an index representing a mixture of both CFR and IMR, gives a dimensionless quantity of vasodilatory strength (60). Such indices will open the way for a more detailed evaluation of the function of the coronary microvasculature. The potential of these indices to support research is clear, still, they will also be helpful to the clinical CMD significance and individualized treatment. Besides that, the MRR and RRR provide new information layers aiming to facilitate the identification of those individuals who are at a higher risk of bad events and furthermore to the personalization of treatments besides what is gotten from variables like CFR, IMR, and endothelial function testing (61).

Right now, in the cath lab, invasive diagnostic systems open a complete range of instruments for the assessment

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

of coronary microvascular function. The most used indices, moreover, those that have been deeply studied and are most relevant, are CFR and IMR as they possess functional and structural components for CMD. In the future, technology like aIMR or continuous thermodilution may be simpler and less operator-dependent and therefore be able to provide even more delicate quantifications (62). Moreover, acetylcholine in endothelial function testing adds detail granularity toward the diagnosis, isolating vasospastic from structural ailment. Hence, clinicians this can isolate the endotypes of CMD, giving them the opportunity to direct the specific-treatment against a particular pathophysiological profile thus patient outcomes in the case of ischemia and nonobstructive CAD sufferers get better (63). Further elaboration of invasive indices, the combinations of these with computational modeling, and the usage of common protocols all signal the paradigm change towards precision cardiology that consequently leads to microvascular disease no longer being one of the blind spots but an active zone of modern clinical practice (64).

5. Cath Lab Workflow and Protocols

A single microvascular diseases evaluation is generally done during or shortly after a total coronary angiogram procedure in the cath lab. During the operation, when a guiding catheter is inserted into the coronary artery's opening, a pressure- and temperature-sensitive guidewire or Doppler flow wire is advanced into the target coronary artery. Such a wire takes pressure and flow velocity measurements for calculating parameters such as coronary flow reserve (CFR) and index of microvascular resistance (IMR). Pharmacological agents-indeed by adenosine-only, to be a way of representing maximal vasodilation for measuring CFR and IMR, while endothelium function and vasospasm are identified by giving a graded dose of acetylcholine (65). Both bolus and continuous procedures may use injection or infusion of saline for the measurement by thermodilution. The procedure is almost stepwise; it involves initial pressure and flow measurements, induction of hyperemia, calculation of resistance and flow indices, and testing of endothelial function, if available. This approach guarantees that both elements of CMD-in the form of morphology and function-have been recognized as important since they are inseparable in one session without doing it again (66).

5.1 Standardized Algorithms and Protocols

Standardization protocols have been mounted for invasive CMD evaluation for use to enhance consistency and reproducibility. Among the ones protocols, possibly the most famous is the CATH CMD protocol for its stepwise justification set of rules in sufferers with ischemia with out obstruction in their coronary arteries (INOCA). It constitutes reluctance and index measurement with IMR mixed with acetylcholine exams to permit the clinician to figure the reference among microvascular angina, vasospasm, or blended variations of angina had been laid low with dysfunction. The protocol has physiological and pharmacological evaluation in defining the CMD endotypes which tell personalised treatment strategies (67).

Among rising evidences is the truth that such standardized protocols are implemented to decorate analysis accuracies albeit would result in higher control consequences usual. The CorMicA trial as an example proved that decreasing angina patients on an invasive CMD test stratified management would reduce angina considerably extra than traditional care (68). In actual existence practice, condensed algorithms reduce operator variability, shorten method time, and make certain critical diagnostic steps aren't overlooked. Structured workflows additionally assist expand training, research and hints that combine medical development with habitual scientific software (69).

Actually, there are predefined protocols to study the laboratory workflow-compete-prompted catheter engagement and guide twine-primarily based measurements, including pharmacological challenges-for standardized protocols like CATH CMD to have turn out to be exempt paradigms for the examination of microvascular disorder in coronary arteries. These approaches could ultimately make clear "regular angiograms" through integrating critical modifications which could yield actionable statistics to enhance sickness consequences in sufferers with angina but without occlusive coronary artery disorder (70).

6. Clinical Relevance and Outcomes

Coronary microvascular disorder and small vessel disorder at the moment are being understood for their important roles as man or woman reasons of ischemia and angina without obstructive epicardial coronary artery ailment. Such early entrants into the artwork of prognosis often obtained both reassurance or the mislabeling and misdiagnosis of their chest pain as "non-cardiac" ache if their coronary angiograms had been every day or almost so: a treatment practice that normally left them very a great deal undertreated. The paradigm shift, however, comes from the fact that invasive CMD detection and SVD in the cath lab can cause centered control (71).

Based at the type of coronary vascular disorder diagnosed with the aid of the doctor-spasm of microvascular, impaired vasodilation, or structural microvascular disorder-the definition or phenotyping of the sort of coronary vascular disorder is possible with

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

useful evaluation equipment which include coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and acetylcholine testing. This will function a baseline to precisely direct remedy: calcium-channel blockers and nitrates for vasospastic styles; beta-blockers and renin-angiotensin device blockers for impaired CFR; or ranolazine for refractory signs and symptoms. This precision treatment takes diagnosis out of treatment and aligns with advice-which is obvious even more on pointers directed recommendation (72).

Risk stratification includes an critical implication for those instances of CMD/SVD identified invasively: they now look like at more lengthy-term threat for primary unfavourable cardiovascular activities-laeky myocardial infarction, HFpEF, and even unexpected dying. This would warrant competitive threat-aspect amendment and preventive treatment with statins and antiplatelet pills, if indicated, for the ones CMD/SVD patients which can be being probed surely for morphology for the duration of catheterisation (73).

6.1 Evidence From Clinical Trials and Registries

The argument for the scientific advantage of invasive detection for CMD/SVD has been bolstered similarly via severa trials and registries. One such quite hooked up trial is the CorMicA (Coronary Microvascular Angina, 2018). In this randomized managed look at, angina sufferers who had unobstructed coronary arteries then underwent invasive functional testing on the cath lab. While stratification in the interventional organization became by means of check consequences, the manipulate institution obtained widespread care. Patients at the cease of 12 months on this version of intervention had been a good deal higher off in phrases of ratings on angina, first-rate of life, and satisfaction with treatment. Such landmark trial has provided textual evidence that invasive testing is probably viable, but clinically meaningful (74).

Such other information from registries, as Women's Ischemia Syndrome Evaluation (WISE), corroborate this. WISE has proven that impaired CFR is an unbiased predictor of unfavourable final results, as a result indicating a prognostic relevance of CMD. To in addition, multicenter registries which have followed invasive protocols, like CATH CMD registry, show that standardized invasive trying out ends in consistencies of diagnosis and links precise CMD phenotypes to focused cures (75). In sum, those studies argue that invasive checking out may also aid remedy choices that may be translated to both symptom comfort and outcome advantages.

6.2 Linking with Other Tests; Their Complementary Roles

As a long way as specific physiological dimension is concerned, cath lab invasive testing has been considerably useful. Non-invasive imaging methods like strain perfusion cardiac magnetic resonance (CMR), PET, and CT perfusion generally tend to offer a part of that huge picture of global, regional myocardial perfusion visible with non-invasive imaging checks. For instance, PET offers very reproducible estimates of CFR, whilst stress CMR may map ischemia patterns subendocardial, that can even be neglected with invasive checking out.

Real-global integration of these marketers will pay off the maximum: invasive testing will become useful when there are signs and symptoms that don't correlate in any respect with non-invasive testing outcomes, or if an angiogram is already going for diagnostic functions. Conversely, if patients are not worthy for invasive strategies, they will be considered in addition for PET or strain CMR as front- line analysis. The integration of the invasive and non-invasive modalities enhances diagnostic self-assurance, refines chance stratification, and aids the improvement of personalised remedy techniques.

7. Limitations, Challenges, and Future Directions

7.1 Current Barriers: Training, Costs, and Underutilization

Identifying a disease such as Coronary Microvascular Dysfunction or Small Vessel Disease has become very common. In context of the measures for catheterization access in the laboratory, it turns out to be an unexplored field of invasive assessment. Several factors act barriers in this regard (78).

7.1.1. Training and operator dependency: Microvascular evaluation isn't always just like routine angiogram. Specialized strategies inclusive of coronary go with the flow reserve (CFR), index of microcirculatory resistance (IMR), and acetylcholine trying out should educate humans in special ways and effects and interpretation especially depend on the performance of the operator's knowledge. Much variability will lead to inconsistent effects. Many cardiology schooling packages nevertheless offer little exposure to superior physiological strategies, for this reason continuing the information hole(79).

7.1.2. Availability and cost: The take a look at by means of those kinds of special strain-temperature guidewires, infusion systems, and pharmacological marketers is expensive, thereby further restraining fashionable acceptance. Budgets are already scarce in low- and

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

center-income areas. The lease of such items would best minimize get entry to further. Even within such excessive-useful resource systems, such compensation frameworks are infrequently spurred in the direction of invasive trying out for CMD as to classify which includes a trendy reimbursable manner, accordingly dampening the ordinary use(80).

7.1.3. Workflow integration: Microvascular testing added time to strategies makes them less attractive to angioplasty cath labs that are busy with high throughput. Along with this, the absence of a universally established modern protocol as well as the once wide medical practice variation pulling even more confidence from the results. Emerging Technologies: Innovation that Drives Feasibility-those technological improvements are step by step addressing such issues. Miniaturized sensors as well as composite multi-modality wires with strain, flow, and temperature measurement capabilities have simplified the procedure immediately. Another device for further development may shorten the test duration and also lessen the dependence on the operator because they can perform a quick assessment using a simplified infusion protocol (81).

7.2 Emerging Technologies: Innovation Driving Feasibility

This is a different method where angiography-derived fractional glide reserve with FFRangio or computational flow dynamics is entering clinical practice. Microvascular resistance and flow reserve are calculated with these methods from the perfusive angiographic pictures. In this way, these are less intrusive methods, and, what is more important, they provide correct results which make them quite promising for a large application in the daily practice (82).

AI and a system of studying might be the tomorrow. An algorithm will have the capacity to investigate both perfusion imaging as well as angiographic records. Perfusion imaging is indeed invasive hemodynamic waves should be utilized for the detection of dreadful CMD phenotypes automatically. Since operator-structured calculation and interpretation would have less effect, reproducibility and confidence in the results would be very much uplifted. In these new multimodal imaging techniques, the combination of invasive physiology with intravascular ultrasound (IVUS) or optical coherence tomography (OCT), a deep insight into both the microvascular structural and functional aspect of disease can be obtained, thus indicating the higher accuracy but still being feasible during the routine catheterization (83).

7.3 Prospects for Broader Adoption: Guidelines and Health Economics

Definitely, the said attack pertains into the future when it comes to cath lab CMD/SVD detection-wise. Most importantly, it is this outcome that most needs integration into standard clinical practice. Current ongoing clinical trials include relatively big steps in this regard. The huge outcome studies in end patients are planned for investigating whether invasive diagnosis of CMD will lead to stratified therapy improving symptoms considering also, perhaps, hard endpoints: myocardial infarction, heart failure, and mortality. Good results from these trials would hasten guideline endorsement on exceedingly obvious outcomes (84).

Health economics will no doubt play a very big part in all this. Invasive tests do incur additional costs, but improved diagnoses and tailored therapy will, in the longer term, lower total costs because there will be reduced rates of hospital readmission, fewer repeat angiograms, and less spending on inappropriate medications. Demonstrating cost-effectiveness to payers and health systems, however, will be a challenge (85).

Currently, updates to the guidelines are already heading that way. CMD has been recognized as clinically significant by the ESC (European Society of Cardiology) and the AHA (American Heart Association), which now recommend advanced or invasive testing for chest pain patients whose coronary arteries are unobstructed. More features like the widely accepted standardized protocols such as the CATH CMD algorithm will increase the accrual of clinical practice and confidence among interventional cardiologists (86).

Even though the demonstration of proof a small change in the cath lab for CMD and simple SVD is a paradigm shift in precision cardiology is something that is very amazing not to mention the fact that it also has its drawbacks. Major problems in the areas of training, procedure complexity, rates, and underutilization are still issues that can discourage the use of this method but a change of the sky due to coming innovations-including the miniaturized sensors, computational flow modelling, and AI-based evaluation-can not only change the landscape of feasibility but also accessibility very quickly. Alongside with the current trial the supportive economic analyses, and the nuanced principal suggestions are also accounted for the improvement of the forecast of the broader adoption. Most likely, what we will see later probably in the next decade is the change of the method from a spot method to one of the daily cath lab assessment of CMD/SVD in which body structure that patients will use for control, diagnosis, and better results in the future (87).

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

8. Conclusion

Over time, microvascular disease of the heart (CMD) and the small vessels of the heart (SVD) have become the main topics of interest besides main coronary artery disease (CAD) in ischemic heart disease. At the beginning, they were considered to be invisible in traditional angiography and to be the offenders of angina, ischemia, and adverse cardiovascular effects in patients who were free from significant epicardial stenosis, and now CMD and SVD have gone beyond the sidelines into the center of the stage (88). Their coming into the limelight was due mainly to the fact that more and more technology examples have been found, and in most of these cases, the separation of physiological from the anatomical paradigm had been done. The change may also become supported by means of the innovations in the cardiac catheterization laboratory (cath lab) that is the main station for diagnosis and intervention of obstructive CAD as well as the most outstanding place for unmasking microvascular and endothelial disorder mechanisms. The big evaluation now possible in the cath lab could be a journey to new ways of diagnosis, prognosis, and therapy, thereby changing the management of ischemia without obstructive coronary artery disease (INOCA) (89).

What is quite amazing is the very fact that at a large timespan both the mechanistic and epidemiological studies have uncovered the presence of CMD and SVD to be very frequent in several patient collectivises. Nearly 50 percent of the patients with angina-like symptoms undergoing angiographic studies that don't show obstructive CAD(90). A rather large percentage of such a sample is from the microvascular disorder. It seems that women are more likely to suffer from this disease, with hormonal influences and smaller vessels being the cause of altered endothelial responses resulting in their susceptibility development. Besides the major risk factors-Diabetes, hypertension, dyslipidemia and systemic inflammation-this added susceptibility is demonstrated by connecting microvascular pathology with systemic metabolic and inflammatory disorders (91). It is this high prevalence of the finding in the population that changes the role of the classical obstructive-front vs. non-obstructive model of class and promotes CMD to the status of a separate clinically relevant entity that demands different evaluation (92).

From the pathophysiological perspective, Coronary Microvascular Disease (CMD) and Small Vessel Disease (SVD) are considered as a combination of the changes in the structure of the body and the functional impairment. Microvascular rarefaction in coronary, fibrosis, and hypertrophy of easy muscle aggravate resistance, at the same time, endothelial disorder impairs vasodilation and increases vasoconstriction (93). This blend causes a low coronary flow reserve (CFR), a mismatch between myocardial oxygen demand and supply. Clinically, it is called angina and is often indistinguishable from obstructive CAD, accompanied by non-specific symptoms such as dyspnea, fatigue, or uncommon pain syndromes. Diagnostics are misled by a lot of incomplete 'standard' angiography (94). Because of the insufficient understanding of these features, patients with CMD are often dismissed or misclassified, which results in ongoing underdiagnosis and undertreatment. Hence, a major transformation of the cath lab will be the change: the chance of functional assessment of coronary access by methods such as CFR, index of microcirculation resistance (IMR), and acetylcholine provocation test will be given. These will objectively record microvascular dysfunction, thus turning clinical suspicion into tangible evidence for guiding treatment (95).

The CATH CMD algorithm, just like many others, is a landmark in microvascular logistics evaluation. They are methods of ensuring reproducibility and minimizing the regular patient's traverse, which is usually very complicated in cases of suspected CMD, together with defining a scientific workflow manner-cath engagement, guidewire development, baseline and hyperaemic measurements, and endothelial testing. The CorMicA trial has been the main source of evidence for protocol-pushed invasive assessment of CMD being linked to better outcomes (96). Patients, while compared to the conventional empirical technique, are likely to become symptomatically better, register an increase in good of lifestyles, and have higher satisfaction after control based totally on tailor-made invasive diagnostics. This is a landmark improvement, indicating that an actionable approach nearer to CMD recognition is not a pedagogical workout but one to provide patient benefit (97).

Over and above symptom treatment, the medical importance of recognition of an invasive CMD comprises the identification of the persons higher-risk for the most severe destructive cardiovascular (MACE) events which can be myocardial infarction, the occurrence of coronary heart failure with preserved ejection fraction (HFpEF), and cardiovascular death. Eventually, CMD identification by catheterization is the rationale for actions in reconfiguration of risk factors, pharmacotherapy and the most diligent follow-ups (98). Such information can also be used for the therapy personalize as some vasospastic endotypes may be pacified by the use of calcium channel blockers, but in the case of beta-blockers, ACE-inhibitors, or new anti-anginal agents may be required in those with impaired CFR or elevated IMRs. It is precision therapy, instead of the one-size-fits-all model and shows the cath lab-based

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

diagnostics utility in the individualization of the therapy (99).

Whether CMD assessment should even be done in a catheter lab is not a stand-alone question. Stress CMR, PET, and CT perfusion all present an invasive finding to which the non-invasive words can add complementary data on total heart perfusion and global flow measurements. Cross-linking both modalities across the lines of invasiveness and non-invasiveness helps formulate a complete diagnosis whereby invasive testing is more suited for pathophysiological clarification and therapy guidance, while non-invasive imaging is universal in accessibility and population-based long-term monitoring. This ensures non-misdiagnosis and adequate treatment for the patients in INOCA (100).

Insoluble and but time-honored hurdles continue to be. These boundaries to general use consist of operator-established skill level, large variance in schooling, fee, and period of the tactics. Many interventionalists have restrained to no experience in carrying out microvascular body structure checking out, and compensation for these processes is missing in health care structures (one zero one). In high-extent cath labs, useful checks of CMD may want to impact the efficiency of patient go with the flow. Additionally, loss of consensus on suggestions and practice heterogeneity is stopping the standardization that would prevent denying so many sufferers those valuable diagnostic evaluations (102).

Expectations about the conditions of CMD and SVD detection in the cath lab are increasing and are heavily dependent on medical evidence, endorsement from tips, and sustainability. It is going to be decided in larger ongoing trials whether CMD-based treatment does better hard outcomes with myocardial infarction and mortality as well as relieving symptoms. So, if such trials would produce good outcomes, then the testing of CMD will be guided through guideline committees into more potent advice instructions which means that it will be deeply ingrained in recurring practice (103). From the perspective of health economics, staging the case for CMD testing is multidimensional: procedural costs are high in the front but the avoidance of re-hospitalizations, unnecessary angiograms, and the use of therapy by the appropriate diagnosis finally improve long-term costs. This will be good for the repayment facility of CMD assessment and set the location for a far wider recognition of this practice in heterogeneous healthcare systems if it is funded against clinical merit but on the basis of cost-effectiveness (104).

The formal popularity and evaluation of coronary microvascular disorder and small vessel disorder is a historical event inside the control of sufferers with ischemic heart disorder. Through the cath lab, the physiology data loca direct, which can enlarge beyond the angiographic silhouette of the epicardial vessels, is key to this change. Non-invasive imaging is coupled with the latest index and common operation methods to invasive CMD testing, which is redefining prognosis and patient control in patients with angina and no obstructive CAD. Patient management has gone up from just comfort assuring of symptoms to pathophysiologically guided-therapy with the final result of improvement (105). There are still some barriers left with education, price, and workflow but all these are being erased step by step through technological advances, scientific evidence, and changing hints. As body structure keeps to take a extra preserve at the practice of cardiology, cath lab-based CMD assessment moves from a place of strength to a common care unit, thus ensuring that the needs of patients with microvascular disease are not forgotten and that the clean evidence-based care which they deserve is received (106).

References

1. Aggarwal, A., Srivastava, S., & Velmurugan, M. (2016). Newer perspectives of coronary artery disease in young. World Journal of Cardiology, 8(12), 728. https://doi.org/10.4330/wjc.v8.i12.728
2. Ahmad, A., Corban, M. T., Toya, T., Attia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., Cohen, M. S., Sara, J. D., Ozcan, I., Lerman, L. O., Kapa, S., Friedman, P. A., & Lerman, A. (2021). Coronary Microvascular Dysfunction and the Risk of Atrial Fibrillation from an Artificial Intelligence-Enabled Electrocardiogram. In Circulation: Arrhythmia and Electrophysiology (Vol. 14, Issue 8, p. E009947). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCEP.121.009947
3. Ayatollahi, H., Gholamhosseini, L., & Salehi, M. (2019). Predicting coronary artery disease: A comparison between two data mining algorithms. BMC Public Health, 19(1). https://doi.org/10.1186/s12889-019-6721-5
4. Bajaj, N. S., Singh, A., Zhou, W., Gupta, A., Fujikura, K., Byrne, C., Harms, H. J., Osborne, M. T., Bravo, P., Andrikopolou, E., Divakaran, S., Bibbo, C. F., Hainer, J., Skali, H., Taqueti, V., Steigner, M., Dorbala, S., Charytan, D. M., Prabhu, S. D., … Di Carli, M. F. (2020). Coronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney Impairment. Circulation, 141(1), 21–33. https://doi.org/10.1161/CIRCULATIONAHA.119.043916
5. Barsness, G. W., & Holmes, D. R. (2014). Coronary artery disease: New approaches without traditional revascularization. In Coronary Artery Disease:

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

New Approaches without Traditional Revascularization. Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-84628-712-1

6. Beneki, E., Dimitriadis, K., Pyrpyris, N., Antonopoulos, A., Aznaouridis, K., Antiochos, P., Fragoulis, C., Lu, H., Meier, D., Tsioufis, K., Fournier, S., Aggeli, C., & Tzimas, G. (2025). Computed Tomography Angiography in the Catheterization Laboratory: A Guide Towards Optimizing Coronary Interventions. In Journal of Cardiovascular Development and Disease (Vol. 12, Issue 1). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/jcdd12010028
7. Bentea, G. P., Berdaoui, B., Morissens, M., van de Borne, P., & Rodriguez, J. C. (2024). Pathophysiology, Diagnosis, and Management of Coronary Artery Disease in the Setting of Atrial Fibrillation. In Journal of the American Heart Association (Vol. 13, Issue 23). American Heart Association Inc. https://doi.org/10.1161/JAHA.124.037552
8. Bock, C., Walter, J. E., Rieck, B., Strebel, I., Rumora, K., Schaefer, I., Zellweger, M. J., Borgwardt, K., & Müller, C. (2024). Enhancing the diagnosis of functionally relevant coronary artery disease with machine learning. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-49390-y
9. Bond, R. M., Ivy, K., Crumbs, T. C., Purewal, V., Obang, S., & Sraow, D. I. S. (2025). Coronary microvascular dysfunction and its role in heart failure with preserved ejection fraction for future prevention and treatment. American Journal of Preventive Cardiology, 22. https://doi.org/10.1016/j.ajpc.2025.100983
10. Bottardi, A., Prado, G. F. A., Lunardi, M., Fezzi, S., Pesarini, G., Tavella, D., Scarsini, R., & Ribichini, F. (2024). Clinical Updates in Coronary Artery Disease: A Comprehensive Review. In Journal of Clinical Medicine (Vol. 13, Issue 16). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/jcm13164600
11. Bruno, R. M., Gori, T., & Ghiadoni, L. (2014). Endothelial function testing and cardiovascular disease: Focus on peripheral arterial tonometry. In Vascular Health and Risk Management (Vol. 10, pp. 577–584). Dove Medical Press Ltd. https://doi.org/10.2147/VHRM.S44471
12. Cacciatore, S., Spadafora, L., Bernardi, M., Galli, M., Betti, M., Perone, F., Nicolaio, G., Marzetti, E., Martone, A. M., Landi, F., Asher, E., Banach, M., Hanon, O., Biondi-Zoccai, G., & Sabouret, P. (2023). Management of Coronary Artery Disease in Older Adults: Recent Advances and Gaps in Evidence. In Journal of Clinical Medicine (Vol. 12, Issue 16). Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/jcm12165233
13. Caullery, B., Riou, L., Marliere, S., Vautrin, E., Piliero, N., Ormerzzano, O., Bouvaist, H., Vanzetto, G., & Barone-Rochette, G. (2025). Prognostic impact of coronary microvascular dysfunction in patients with myocardial infarction evaluated by new angiography-derived index of microvascular resistance. IJC Heart and Vasculature, 56. https://doi.org/10.1016/j.ijcha.2024.101575
14. Choi, K. H., Dai, N., Li, Y. L., Kim, J., Shin, D., Lee, S. H., Joh, H. S., Kim, H. K., Jeon, K. H., Ha, S. J., Kim, S. M., Jang, M. J., Park, T. K., Yang, J. H., Song, Y. Bin, Hahn, J. Y., Doh, J. H., Shin, E. S., Choi, S. H., … Lee, J. M. (2021). Functional Coronary Angiography–Derived Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 14(15), 1670–1684. https://doi.org/10.1016/j.jcin.2021.05.027
15. Chu, M., Wu, P., Li, G., Yang, W., Gutiérrez-Chico, J. L., & Tu, S. (2023). Advances in Diagnosis, Therapy, and Prognosis of Coronary Artery Disease Powered by Deep Learning Algorithms. In JACC: Asia (Vol. 3, Issue 1, pp. 1–14). Elsevier Inc. https://doi.org/10.1016/j.jacasi.2022.12.005
16. Collet, C., Sonck, J., Leipsic, J., Monizzi, G., Buytaert, D., Kitslaar, P., Andreini, D., & De Bruyne, B. (2021). Implementing Coronary Computed Tomography Angiography in the Catheterization Laboratory. In JACC: Cardiovascular Imaging (Vol. 14, Issue 9, pp. 1846–1855). Elsevier Inc. https://doi.org/10.1016/j.jcmg.2020.07.048
17. Collet, C., Yong, A., Munhoz, D., Akasaka, T., Berry, C., Blair, J. E. A., Collison, D., Engstrøm, T., Escaned, J., Fearon, W. F., Ford, T., Gori, T., Koo, B. K., Low, A. F., Miner, S., Ng, M. K. C., Mizukami, T., Shimokawa, H., Smilowitz, N. R., … Ali, Z. A. (2024). A Systematic Approach to the Evaluation of the Coronary Microcirculation Using Bolus Thermodilution: CATH CMD. In Journal of the Society for Cardiovascular Angiography and Interventions (Vol. 3, Issue 7). Elsevier B.V. https://doi.org/10.1016/j.jscai.2024.101934
18. Crea, F., Montone, R. A., & Rinaldi, R. (2022). Pathophysiology of Coronary Microvascular Dysfunction. In Circulation Journal (Vol. 86, Issue 9, pp. 1319–1328). Japanese Circulation Society. https://doi.org/10.1253/circj.CJ-21-0848

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

19. Cury, R. C., Leipsic, J., Abbara, S., Achenbach, S., Berman, D., Bittencourt, M., Budoff, M., Chinnaiyan, K., Choi, A. D., Ghoshhajra, B., Jacobs, J., Koweek, L., Lesser, J., Maroules, C., Rubin, G. D., Rybicki, F. J., Shaw, L. J., Williams, M. C., Williamson, E., … Blankstein, R. (2022). CAD-RADSTM 2.0 - 2022 Coronary Artery Disease-Reporting and Data System: An Expert Consensus Document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR), and the North America Society of Cardiovascular Imaging (NASCI). Journal of Cardiovascular Computed Tomography, 16(6), 536–557. https://doi.org/10.1016/j.jcct.2022.07.002
20. da Luz, P. L., Bertini, P. J., & Favarato, D. (2005). Noninvasive detection of coronary artery disease -- challenges for prevention of disease and clinical events. In Clinics (São Paulo, Brazil) (Vol. 60, Issue 5, pp. 415–428). https://doi.org/10.1590/s1807-59322005000500011
21. Daggubati, R., Rigatelli, G., Nguyen, T., Nanjundappa, A., & Chambers, C. (2014). Roles of cardiac catheterization laboratory directors. In Chinese Medical Journal (Vol. 127, Issue 6, pp. 1194–1196). Chinese Medical Association. https://doi.org/10.3760/cma.j.issn.0366-6999.20133280
22. Dai, N., Che, W., Liu, L., Zhang, W., Yin, G., Xu, B., Xu, Y., Duan, S., Yu, H., Li, C., Yao, K., Huang, D., & Ge, J. (2021). Diagnostic Value of Angiography-Derived IMR for Coronary Microcirculation and Its Prognostic Implication After PCI. Frontiers in Cardiovascular Medicine, 8. https://doi.org/10.3389/fcvm.2021.735743
23. D'Amario, D., Laborante, R., Bianchini, E., Ciliberti, G., Paglianiti, D. A., Galli, M., Restivo, A., Stolfo, D., Vergallo, R., Rosano, G. M. C., Crea, F., Lam, C. S. P., Lund, L. H., Metra, M., Patti, G., & Savarese, G. (2024). Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis. ESC Heart Failure, 11(4), 2063–2075. https://doi.org/10.1002/ehf2.14626
24. de Jong, E. A. M., Namba, H. F., Boerhout, C. K. M., Feenstra, R. G. T., Woudstra, J., Vink, C. E. M., Appelman, Y., Beijk, M. A. M., Piek, J. J., & van de Hoef, T. P. (2025). Assessment of coronary endothelial dysfunction using contemporary coronary function testing. International Journal of Cardiology, 418. https://doi.org/10.1016/j.ijcard.2024.132640
25. De Maria, G. L., Garcia-Garcia, H. M., Scarsini, R., Hideo-Kajita, A., Gonzalo López, N., Leone, A. M., Sarno, G., Daemen, J., Shlofmitz, E., Jeremias, A., Tebaldi, M., Bezerra, H. G., Tu, S., Lemos, P. A., Ozaki, Y., Dan, K., Collet, C., Banning, A. P., Barbato, E., … Waksman, R. (2020). Novel Indices of Coronary Physiology: Do We Need Alternatives to Fractional Flow Reserve? In Circulation: Cardiovascular Interventions (Vol. 13, Issue 4, p. E008487). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008487
26. Demir, O. M., Rahman, H., Van De Hoef, T. P., Escaned, J., Piek, J. J., Plein, S., & Perera, D. (2022). Invasive and non-invasive assessment of ischaemia in chronic coronary syndromes: Translating pathophysiology to clinical practice. In European Heart Journal (Vol. 43, Issue 2, pp. 105–117). Oxford University Press. https://doi.org/10.1093/eurheartj/ehab548
27. Díez-delhoyo, F., Gutiérrez-Ibañes, E., Loughlin, G., Sanz-Ruiz, R., Vázquez-Álvarez, M. E., Sarnago-Cebada, F., Angulo-Llanos, R., Casado-Plasencia, A., Elízaga, J., & Diáz, F. F. A. (2015). Coronary physiology assessment in the catheterization laboratory. World Journal of Cardiology, 7(9), 525. https://doi.org/10.4330/wjc.v7.i9.525
28. Duggan, J. P., Peters, A. S., Trachiotis, G. D., & Antevil, J. L. (2022). Epidemiology of Coronary Artery Disease. In Surgical Clinics of North America (Vol. 102, Issue 3, pp. 499–516). W.B. Saunders. https://doi.org/10.1016/j.suc.2022.01.007
29. Edvardsen, T., Asch, F. M., Davidson, B., Delgado, V., DeMaria, A., Dilsizian, V., Gaemperli, O., Garcia, M. J., Kamp, O., Lee, D. C., Neglia, D., Neskovic, A. N., Pellikka, P. A., Plein, S., Sechtem, U., Shea, E., Sicari, R., Villines, T. C., Lindner, J. R., & Popescu, B. A. (2022). Non-Invasive Imaging in Coronary Syndromes: Recommendations of The European Association of Cardiovascular Imaging and the American Society of Echocardiography, in Collaboration with The American Society of Nuclear Cardiology, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. Journal of the American Society of Echocardiography, 35(4), 329–354. https://doi.org/10.1016/j.echo.2021.12.012
30. Escaned, J., & Kakuta, T. (2021). Coronary flow reserve and coronary flow capacity at a time of shifting paradigms of ischaemic heart disease. In EuroIntervention (Vol. 16, Issue 18, pp. E1463–

E1465). Europa Group. https://doi.org/10.4244/EIJV16I18A264

31. Feenstra, R. G. T., Seitz, A., Boerhout, C. K. M., de Winter, R. J., Ong, P., Beijk, M. A. M., Piek, J. J., Sechtem, U., & van de Hoef, T. P. (2023). Reference values for intracoronary Doppler flow velocity-derived hyperaemic microvascular resistance index. International Journal of Cardiology, 371, 16–20. https://doi.org/10.1016/j.ijcard.2022.09.054
32. Feger, S., Ibes, P., Napp, A. E., Lembcke, A., Laule, M., Dreger, H., Bokelmann, B., Davis, G. K., Roditi, G., Diez, I., Schröder, S., Plank, F., Maurovich-Horvat, P., Vidakovic, R., Veselka, J., Ilnicka-Suckiel, M., Erglis, A., Benedek, T., Rodriguez-Palomares, J., … Dewey, M. (2021). Clinical pre-test probability for obstructive coronary artery disease: insights from the European DISCHARGE pilot study. European Radiology, 31(3), 1471–1481. https://doi.org/10.1007/s00330-020-07175-z
33. Gagliardi, M. G., Formigari, R., Perrone, M. A., Pomiato, E., Fanisio, F., Panebianco, M., Barracano, R., Guccione, P., Palmieri, R., Raponi, M., & Galletti, L. (2023). Changes in the Cath Lab in the Treatment of Adult Patients with Congenital Heart Disease: A 12-Year Experience in a Single Referral Center with the Establishment of a Dedicated Working Group. Journal of Cardiovascular Development and Disease, 10(8). https://doi.org/10.3390/jcdd10080314
34. Gall, E., Barone-Rochette, G., Picard, F., Castillo Tovar, J., Poinsignon, H., Clement, A., Singh, M., Lequipar, A., Lafont, A., Toupin, S., Henry, P., Pezel, T., Reiber, J. H. C., & Dillinger, J. G. (n.d.). Interventional Cardiology-Invasive Imaging and Functional Assessment, Intracoronary Flow and Pressure Measurements Comparison of angiography-derived index of microcirculatory resistance measurements between low and high frame-rate acquisitions: the prospective ADMIRAL-study. https://academic.oup.com/eurheartj/article/45/Supplement_1/ehae666.2347/7837758
35. Gallinoro, E., Bertolone, D. T., Mizukami, T., Paolisso, P., Bermpeis, K., Munhoz, D., Sakai, K., Seki, R., Ohashi, H., Esposito, G., Caglioni, S., Mileva, N., Leone, A., Candreva, A., Belmonte, M., Storozhenko, T., Viscusi, M. M., Vanderheyden, M., Wyffels, E., … De Bruyne, B. (2023). Continuous vs Bolus Thermodilution to Assess Microvascular Resistance Reserve. JACC: Cardiovascular Interventions, 16(22), 2767–2777. https://doi.org/10.1016/j.jcin.2023.09.027
36. Gallinoro, E., Candreva, A., Colaiori, I., Kodeboina, M., Fournier, S., Nelis, O., Gioia, G. DI, Sonck, J., Van'T Veer, M., Pijls, N. H. J., Collet, C., & De Bruyne, B. (2021). Thermodilution-derived volumetric resting coronary blood flow measurement in humans. EuroIntervention, 17(8), E672–E679. https://doi.org/10.4244/EIJ-D-20-01092
37. Gao, Z., Qian, X. H., Ke, J. Y., Lin, K., Zhu, J. H., Zhou, X., Zhou, H., & Wang, L. G. (2025). Angiography-derived index of microcirculatory resistance as a novel tool to assess coronary microvascular dysfunction in patients with diabetic cardiomyopathy. International Journal of Cardiology, 431. https://doi.org/10.1016/j.ijcard.2025.133220
38. Gupta, A. (2019). APPLICATION OF CONTINUOUS QUALITY IMPROVEMENT PROGRAM THROGH DMAIC MODEL IN OFFERING SAFE AND EFFECTIVE SERVICES IN CARDIAC CATHETERIZATION LABORATORY. International Journal of Advanced Research, 7(7), 823–837. https://doi.org/10.21474/IJAR01/9429
39. Hamidabad, N. M., Kanaji, Y., Ozcan, I., Sara, J. D. S., Ahmad, A., Lerman, L. O., & Lerman, A. (2024). Prognostic Implications of Resistive Reserve Ratio in Patients With Nonobstructive Coronary Artery Disease With Myocardial Bridging. Journal of the American Heart Association , 13(15). https://doi.org/10.1161/JAHA.124.035000
40. Hong, D., Shin, D., Lee, S. H., Joh, H. S., Choi, K. H., Kim, H. K., Ha, S. J., Park, T. K., Yang, J. H., Song, Y. Bin, Hahn, J. Y., Choi, S. H., Gwon, H. C., & Lee, J. M. (2023). Prognostic Impact of Coronary Microvascular Dysfunction According to Different Patterns by Invasive Physiologic Indexes in Symptomatic Patients With Intermediate Coronary Stenosis. Circulation: Cardiovascular Interventions, 16(3), E012621. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012621
41. Jansen, T. P. J., de Vos, A., Paradies, V., Dimitriu-Leen, A., Crooijmans, C., Elias-Smale, S., Rodwell, L., Maas, A. H. E. M., Smits, P. C., Pijls, N., van Royen, N., & Damman, P. (2023). Continuous Versus Bolus Thermodilution-Derived Coronary Flow Reserve and Microvascular Resistance Reserve and Their Association With Angina and Quality of Life in Patients With Angina and Nonobstructive Coronaries: A Head-to-Head Comparison. Journal of the American Heart Association, 12(16). https://doi.org/10.1161/JAHA.123.030480

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(6), 602-620 | ISSN:2251-6727

42. Kelshiker, M. A., Seligman, H., Howard, J. P., Rahman, H., Foley, M., Nowbar, A. N., Rajkumar, C. A., Shun-Shin, M. J., Ahmad, Y., Sen, S., Al-Lamee, R., & Petraco, R. (2022). Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. In European Heart Journal (Vol. 43, Issue 16, pp. 1582–1593). Oxford University Press. https://doi.org/10.1093/eurheartj/ehab775
43. Kern, M. J., Lerman, A., Bech, J. W., De Bruyne, B., Eeckhout, E., Fearon, W. F., Higano, S. T., Lim, M. J., Meuwissen, M., Piek, J. J., Pijls, N. H. J., Siebes, M., & Spaan, J. A. E. (2006). Physiological assessment of coronary artery disease in the cardiac catheterization laboratory: A scientific statement from the American Heart Association Committee on diagnostic and interventional cardiac catheterization, council on clinical cardiology. In Circulation (Vol. 114, Issue 12, pp. 1321–1341). https://doi.org/10.1161/CIRCULATIONAHA.106.177276
44. Khandkar, C., Rehan, R., Ravindran, J., & Yong, A. (2025). An updated review on therapeutic strategies in coronary microvascular dysfunction. International Journal of Cardiology, 428. https://doi.org/10.1016/j.ijcard.2025.133128
45. Kiris¸li, H. A. K., Schaap, M., Metz, C. T., Dharampal, A. S., Meijboom, W. B., Papadopoulou, S. L., Dedic, A., Nieman, K., De Graaf, M. A., Meijs, M. F. L., Cramer, M. J., Broersen, A., Cetin, S., Eslami, A., Flórez-Valencia, L., Lor, K. L., Matuszewski, B., Melki, I., Mohr, B., … Van Walsum, T. (n.d.). Standardized evaluation framework for evaluating coronary artery stenosis detection, stenosis quantification and lumen segmentation algorithms in Computed Tomography Angiography.
46. Kohsaka, S., Ejiri, K., Takagi, H., Watanabe, I., Gatate, Y., Fukushima, K., Nakano, S., & Hirai, T. (2023). Diagnostic and Therapeutic Strategies for Stable Coronary Artery Disease Following the ISCHEMIA Trial. In JACC: Asia (Vol. 3, Issue 1, pp. 15–30). Elsevier Inc. https://doi.org/10.1016/j.jacasi.2022.10.013
47. Kübler, J., Brendel, J. M., Küstner, T., Walterspiel, J., Hagen, F., Paul, J. F., Nikolaou, K., Gassenmaier, S., Tsiflikas, I., Burgstahler, C., Greulich, S., Winkelmann, M. T., & Krumm, P. (2024). Artificial intelligence-enhanced detection of subclinical coronary artery disease in athletes: diagnostic performance and limitations. International Journal of Cardiovascular Imaging, 40(12), 2503–2511. https://doi.org/10.1007/s10554-024-03256-y
48. Kuvin, J. T., & Karas, R. H. (2003). Clinical utility of endothelial function testing: Ready for prime time? In Circulation (Vol. 107, Issue 25, pp. 3243–3247). https://doi.org/10.1161/01.CIR.0000075928.54461.33
49. Mageed, L. (n.d.). Coronary Artery Disease: Pathogenesis, Progression of Atherosclerosis and Risk Factors. https://doi.org/10.31031/OJCHD.2018.02.000545
50. Mancini, G. B. J., Gosselin, G., Chow, B., Kostuk, W., Stone, J., Yvorchuk, K. J., Abramson, B. L., Cartier, R., Huckell, V., Tardif, J. C., Connelly, K., Ducas, J., Farkouh, M. E., Gupta, M., Juneau, M., O'Neill, B., Raggi, P., Teo, K., Verma, S., & Zimmermann, R. (2014). Canadian Cardiovascular Society Guidelines for the diagnosis and management of stable ischemic heart disease. Canadian Journal of Cardiology, 30(8), 837–849. https://doi.org/10.1016/j.cjca.2014.05.013
51. Marano, P., Wei, J., & Merz, C. N. B. (2023). Coronary Microvascular Dysfunction: What Clinicians and Investigators Should Know. In Current Atherosclerosis Reports (Vol. 25, Issue 8, pp. 435–446). Springer. https://doi.org/10.1007/s11883-023-01116-z
52. Matsuzawa, Y., & Lerman, A. (2014). Endothelial dysfunction and coronary artery disease: Assessment, prognosis, and treatment. In Coronary Artery Disease (Vol. 25, Issue 8, pp. 713–724). Lippincott Williams and Wilkins. https://doi.org/10.1097/MCA.0000000000000178
53. Mejía-Rentería, H., Wang, L., Chipayo-Gonzales, D., van de Hoef, T. P., Travieso, A., Espejo, C., Núñez-Gil, I. J., Macaya, F., Gonzalo, N., & Escaned, J. (2023). Angiography-derived assessment of coronary microcirculatory resistance in patients with suspected myocardial ischaemia and non-obstructive coronary arteries. EuroIntervention, 18(16), E1348–E1356. https://doi.org/10.4244/EIJ-D-22-00579
54. Mela, J. La, Riou, L., & Barone-Rochette, G. (2024). Coronary microvascular dysfunction and atrial reservoir function. Cardiovascular Ultrasound, 22(1). https://doi.org/10.1186/s12947-024-00324-0
55. Meuwissen, M., Siebes, M., Chamuleau, S. A., Verhoeff, B.-J., Henriques, J. P., Spaan, J. A., & Piek, J. J. (2009). Role of fractional and coronary flow reserve in clinical decision making in intermediate coronary lesions. Interventional Cardiology, 1(2), 237–255. https://doi.org/10.2217/ica.09.33
56. Meyer, E. (2021). Coronary Artery Disease: Diagnosis and Prevention ARTICLE HISTORY. In

COMMENTARY JOURNAL OF CONTEMPORARY MEDICAL EDUCATION.

57. Minten, L., McCutcheon, K., Vanhaverbeke, M., Wouters, L., Bézy, S., Lesizza, P., Jentjens, S., Frederiks, P., Bringmans, T., Voigt, J. U., Adriaenssens, T., Desmet, W., Sinnaeve, P., Jacobs, S., Verbrugghe, P., Meuris, B., Janssens, S., Fearon, W. F., Bennett, J., & Dubois, C. (2025). Coronary Physiological Indexes to Evaluate Myocardial Ischemia in Patients With Aortic Stenosis Undergoing Valve Replacement. JACC: Cardiovascular Interventions, 18(2), 201–212. https://doi.org/10.1016/j.jcin.2024.10.024
58. Moss, A. J., Williams, M. C., Newby, D. E., & Nicol, E. D. (2017). The Updated NICE Guidelines: Cardiac CT as the First-Line Test for Coronary Artery Disease. In Current Cardiovascular Imaging Reports (Vol. 10, Issue 5). Current Medicine Group LLC 1. https://doi.org/10.1007/s12410-017-9412-6
59. Nakano, S., Kohsaka, S., Chikamori, T., Fukushima, K., Kobayashi, Y., Kozuma, K., Manabe, S., Matsuo, H., Nakamura, M., Ohno, T., Sawano, M., Toda, K., Ueda, Y., Yokoi, H., Gatate, Y., Kasai, T., Kawase, Y., Matsumoto, N., Mori, H., … Kimura, T. (2022). JCS 2022 Guideline Focused Update on Diagnosis and Treatment in Patients With Stable Coronary Artery Disease. In Circulation Journal (Vol. 86, Issue 5, pp. 882–915). Japanese Circulation Society. https://doi.org/10.1253/circj.CJ-21-1041
60. Namba, H. F., Boerhout, C. K. M., Damman, P., Kunadian, V., Escaned, J., Ong, P., Perera, D., Berry, C., van de Hoef, T. P., & Piek, J. J. (2025). Invasive coronary function testing in clinical practice: Implementing the 2024 ESC guidelines on chronic coronary syndromes. International Journal of Cardiology, 430. https://doi.org/10.1016/j.ijcard.2025.133176
61. Nardone, M., McCarthy, M., Ardern, C. I., Nield, L. E., Toleva, O., Cantor, W. J., & Miner, S. E. S. (2022). Concurrently Low Coronary Flow Reserve and Low Index of Microvascular Resistance Are Associated with Elevated Resting Coronary Flow in Patients with Chest Pain and Nonobstructive Coronary Arteries. Circulation: Cardiovascular Interventions, 15(3), 011323. https://doi.org/10.1161/CIRCINTERVENTIONS.121.011323
62. Nolte, F., Van De Hoef, T. P., Meuwissen, M., Voskuil, M., Chamuleau, S. A. J., Henriques, J. P. S., Verberne, H. J., Van Eck-Smit, B. L. F., Koch, K. T., De Winter, R. J., Spaan, J. A. E., Tijssen, J. G. P., Siebes, M., & Piek, J. J. (2014). Increased hyperaemic coronary microvascular resistance adds to the presence of myocardial ischaemia. EuroIntervention, 9(12), 1423–1431. https://doi.org/10.4244/EIJV9I12A240
63. Ohashi, H., Bouisset, F., Buytaert, D., Seki, R., Sonck, J., Sakai, K., Belmonte, M., Kitslaar, P., Updegrove, A., Amano, T., Andreini, D., De Bruyne, B., & Collet, C. (2023). Coronary CT Angiography in the Cath Lab: Leveraging Artificial Intelligence to Plan and Guide Percutaneous Coronary Intervention. In Interventional Cardiology: Reviews, Research, Resources (Vol. 18). Radcliffe Medical Media. https://doi.org/10.15420/icr.2023.12
64. Park, S., & Koo, B.-K. (2023). Physiologic Assessment of Coronary Artery Disease: Past, Present and Future. Journal of Cardiovascular Intervention, 2(2), 66. https://doi.org/10.54912/jci.2022.0022
65. Petch, J., Tabja Bortesi, J. P., Sheth, T., Natarajan, M., Pinilla-Echeverri, N., Di, S., Bangdiwala, S. I., Mosleh, K., Ibrahim, O., Bainey, K. R., Dobranowski, J., Becerra, M. P., Sonier, K., & Schwalm, J. D. (2025). Coronary Computed Tomographic Angiography to Optimize the Diagnostic Yield of Invasive Angiography for Low-Risk Patients Screened With Artificial Intelligence: Protocol for the CarDIA-AI Randomized Controlled Trial. JMIR Research Protocols, 14. https://doi.org/10.2196/71726
66. Pompei, G., Ganzorig, N., Kotanidis, C. P., Alkhalil, M., Collet, C., Sinha, A., Perera, D., Beltrame, J., & Kunadian, V. (2024). Novel diagnostic approaches and management of coronary microvascular dysfunction. American Journal of Preventive Cardiology, 19. https://doi.org/10.1016/j.ajpc.2024.100712
67. Reddy, S., & Lee, K. S. (2018). Role of Cardiac Catheterization Lab Post Resuscitation in Patients with ST Elevation Myocardial Infarction. Current Cardiology Reviews, 14(2), 85–91. https://doi.org/10.2174/1573403x14666180517080828
68. Reed, G. W., Tushman, M. L., & Kapadia, S. R. (2018). Operational Efficiency and Effective Management in the Catheterization Laboratory: JACC Review Topic of the Week. In Journal of the American College of Cardiology (Vol. 72, Issue 20, pp. 2507–2517). Elsevier USA. https://doi.org/10.1016/j.jacc.2018.08.2179
69. Rehan, R., Yong, A., Ng, M., Weaver, J., & Puranik, R. (2023a). Coronary microvascular dysfunction: A review of recent progress and clinical implications. In Frontiers in Cardiovascular Medicine (Vol. 10). Frontiers Media S.A. https://doi.org/10.3389/fcvm.2023.1111721

70. Rocco, E., Grimaldi, M. C., Maino, A., Cappannoli, L., Pedicino, D., Liuzzo, G., & Biasucci, L. M. (2022). Advances and Challenges in Biomarkers Use for Coronary Microvascular Dysfunction: From Bench to Clinical Practice. In Journal of Clinical Medicine (Vol. 11, Issue 7). MDPI. https://doi.org/10.3390/jcm11072055
71. Rwebembera, J., Aliku, T., Kayima, J., Lubega, S., Sebatta, E., Kiggundu, B., Kirenzi, D., Nyakoojo, W., Mondo, C., Kumar, K., Ratnayaka, K., Qureshi, S., Daluvoy, S., Lwabi, P., Omagino, J., Sable, C., Longenecker, C., Simon, D., Costa, M., & Okello, E. (2021). Starting and operating a public cardiac catheterization laboratory in a low resource setting: The eight-year story of the Uganda heart institute catheter laboratory. In Global Heart (Vol. 16, Issue 1). Ubiquity Press. https://doi.org/10.5334/GH.859
72. Safri, Z. (2018). Management of coronary artery disease. IOP Conference Series: Earth and Environmental Science, 125(1). https://doi.org/10.1088/1755-1315/125/1/012125
73. Sai, N., & Min, D. (2024). Advanced Diagnosis of Polycystic Ovarian Syndrome using Machine Learning and Multimodal Data Integration. In IJACSA) International Journal of Advanced Computer Science and Applications (Vol. 15, Issue 6). www.ijacsa.thesai.org
74. Saraste, A., & Knuuti, J. (2020). ESC 2019 guidelines for the diagnosis and management of chronic coronary syndromes: Recommendations for cardiovascular imaging. In Herz (Vol. 45, Issue 5, pp. 409–420). Springer Medizin. https://doi.org/10.1007/s00059-020-04935-x
75. Serafi, A. S., Hussain, Z., Bafail, M. A., & Sohail, S. (2023). PATHOPHYSIOLOGY OF CORONARY HEART DISEASE. In INT. J. BIOL. BIOTECH (Vol. 20, Issue 4).
76. Singh Yadav, P., Kumar Meena, A., Lal Verma, H., & Ram Meena, R. (n.d.). CLINICAL PROFILE OF CORONARY ARTERY DISEASE IN WOMEN. International Journal of Academic Medicine and Pharmacy. https://doi.org/10.47009/jamp.2023.5.3.476
77. Sinha, A., Rahman, H., & Perera, D. (2020). Coronary microvascular disease: current concepts of pathophysiology, diagnosis and management. In Cardiovascular Endocrinology and Metabolism (Vol. 10, Issue 1, pp. 22–30). Lippincott Williams and Wilkins. https://doi.org/10.1097/XCE.0000000000000223
78. Smilowitz, N. R., Toleva, O., Chieffo, A., Perera, D., & Berry, C. (2023). Coronary Microvascular Disease in Contemporary Clinical Practice. In Circulation: Cardiovascular Interventions (Vol. 16, Issue 6, p. E012568). Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012568
79. Solberg, O. G., Ragnarsson, A., Kvarsnes, A., Endresen, K., Kongsgård, E., Aakhus, S., Gullestad, L., Stavem, K., & Aaberge, L. (2014). Reference interval for the index of coronary microvascular resistance. EuroIntervention, 9(9), 1069–1075. https://doi.org/10.4244/EIJV9I9A181
80. Stegehuis, V. E., Wijntjens, G. W., Piek, J. J., & van de Hoef, T. P. (2018). Fractional Flow Reserve or Coronary Flow Reserve for the Assessment of Myocardial Perfusion: Implications of FFR as an Imperfect Reference Standard for Myocardial Ischemia. In Current Cardiology Reports (Vol. 20, Issue 9). Current Medicine Group LLC 1. https://doi.org/10.1007/s11886-018-1017-4
81. Sun, X., Yin, Y., Yang, Q., & Huo, T. (2023). Artificial intelligence in cardiovascular diseases: diagnostic and therapeutic perspectives. In European Journal of Medical Research (Vol. 28, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s40001-023-01065-y
82. Sung Joh, H., Shin, D., Lee, J. M., Lee, S. H., Hong, D., Choi, K. H., Hwang, D., Boerhout, C. K. M., De Waard, G. A., Jung, J. H., Mejia-Renteria, H., Hoshino, M., Echavarria-Pinto, M., Meuwissen, M., Matsuo, H., Madera-Cambero, M., Eftekhari, A., Effat, M. A., Murai, T., … Van De Hoef, T. P. (2022). Prognostic Impact of Coronary Flow Reserve in Patients With Reduced Left Ventricular Ejection Fraction. Journal of the American Heart Association, 11(15). https://doi.org/10.1161/JAHA.122.025841
83. Taqueti, V. R., & Di Carli, M. F. (2018). Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. In Journal of the American College of Cardiology (Vol. 72, Issue 21, pp. 2625–2641). Elsevier USA. https://doi.org/10.1016/j.jacc.2018.09.042
84. Taqueti, V. R., Shah, A. M., Everett, B. M., Pradhan, A. D., Piazza, G., Bibbo, C., Hainer, J., Morgan, V., Carolina do A. H. de Souza, A., Skali, H., Blankstein, R., Dorbala, S., Goldhaber, S. Z., Le May, M. R., Chow, B. J. W., deKemp, R. A., Hage, F. G., Beanlands, R. S., Libby, P., … Di Carli, M. F. (2023). Coronary Flow Reserve, Inflammation, and Myocardial Strain: The CIRT-CFR Trial. JACC: Basic to Translational Science, 8(2), 141–151. https://doi.org/10.1016/j.jacbts.2022.08.009
85. Tas, A., Alan, Y., Kara Tas, I., Umman, S., Parker, K. H., Van De Hoef, T. P., Sezer, M., & Piek, J. J. (2025). The impact of high microvascular resistance on coronary wave energetics depends on

coronary microvascular functionality. European Heart Journal Open, 5(3). https://doi.org/10.1093/ehjopen/oeaf050

86. Themistocleous, I.-C., Stefanakis, M., & Douda, H. T. (2017). Coronary Heart Disease Part I: Pathophysiology and Risk Factors. In Journal of Physical Activity. www.panr.com.cy
87. Toya, T., Corban, M. T., Park, J. Y., Ahmad, A., Özcan, I., Sebaali, F., Sara, J. D., Gulati, R., Lerman, L. O., & Lerman, A. (2021). Prognostic impact and clinical outcomes of coronary flow reserve and hyperaemic microvascular resistance. EuroIntervention, 17(7), 569–575. https://doi.org/10.4244/EIJ-D-20-00853
88. van de Hoef, T. P., Lee, J. M., Boerhout, C. K. M., de Waard, G. A., Jung, J. H., Lee, S. H., Mejía-Rentería, H., Hoshino, M., Echavarria-Pinto, M., Meuwissen, M., Matsuo, H., Madera-Cambero, M., Eftekhari, A., Effat, M. A., Murai, T., Marques, K., Doh, J. H., Christiansen, E. H., Banerjee, R., … Piek, J. J. (2022). Combined Assessment of FFR and CFR for Decision Making in Coronary Revascularization: From the Multicenter International ILIAS Registry. JACC: Cardiovascular Interventions, 15(10), 1047–1056. https://doi.org/10.1016/j.jcin.2022.03.016
89. Vancheri, F., Longo, G., Vancheri, S., & Henein, M. (2020). Coronary microvascular dysfunction. In Journal of Clinical Medicine (Vol. 9, Issue 9, pp. 1–38). MDPI. https://doi.org/10.3390/jcm9092880
90. Vijayalakshmi, I. B., Nemani, L., Kher, M., & Kumar, A. (2023). The Gamut of Coronary Artery Disease in Indian Wome. In Indian Journal of Cardiovascular Disease in Women - WINCARS (Vol. 8, Issue 1, pp. 43–51). Scientific Scholar LLC. https://doi.org/10.25259/mm_ijcdw_404
91. Voruganti, D., & Mehta, J. L. (2021). Coronary microvascular disease: diagnostic evaluation. In Vessel Plus (Vol. 5). OAE Publishing Inc. https://doi.org/10.20517/2574-1209.2021.60
92. Wang, B., Gao, Y., Zhao, Y., Jia, P., Han, J., Li, H., Zhang, Y., & Xu, Y. (2023). Prognostic Value of Angiography-Derived Index of Microcirculatory Resistance in Patients with Coronary Artery Disease Undergoing Rotational Atherectomy. Reviews in Cardiovascular Medicine, 24(5). https://doi.org/10.31083/j.rcm2405131
93. Wang, D., Li, X., Feng, W., Zhou, H., Peng, W., & Wang, X. (2024). Diagnostic and prognostic value of angiography-derived index of microvascular resistance: a systematic review and meta-analysis. In Frontiers in Cardiovascular Medicine (Vol. 11). Frontiers Media SA. https://doi.org/10.3389/fcvm.2024.1360648
94. Wang, Y., Wang, B., Ling, H., Li, Y., Fu, S., Xu, M., Li, B., Liu, X., Wang, Q., Li, A., Zhang, X., & Liu, M. (2024). Navigating the Landscape of Coronary Microvascular Research: Trends, Triumphs, and Challenges Ahead. In Reviews in Cardiovascular Medicine (Vol. 25, Issue 8). IMR Press Limited. https://doi.org/10.31083/j.rcm2508288
95. Widmer, R. J., Rosol, Z. P., Banerjee, S., Sandoval, Y., & Schussler, J. M. (2024). Cardiac Computed Tomography Angiography in the Evaluation of Coronary Artery Disease: An Interventional Perspective. In Journal of the Society for Cardiovascular Angiography and Interventions (Vol. 3, Issue 3). Elsevier B.V. https://doi.org/10.1016/j.jscai.2024.101301
96. Wilson, P. W. (1987). Diabetes Mellitus and Coronary Heart Disease.
97. Wu, J., Yang, D., Zhang, Y., Xian, H., Weng, Z., Ji, L., & Yang, F. (2025). Non-invasive imaging innovation: FFR-CT combined with plaque characterization, safeguarding your cardiac health. In Journal of Cardiovascular Computed Tomography (Vol. 19, Issue 1, pp. 152–158). Elsevier Inc. https://doi.org/10.1016/j.jcct.2024.08.008
98. Wu, Z. F., Tao, S. X., Su, W. T., Chen, S., Xu, B. Da, Zong, G. J., & Wu, G. Y. (2025). Development and validation of a novel coronary artery disease risk prediction model. In Journal of Translational Medicine (Vol. 23, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s12967-024-05789-1
99. Yamazaki, T., Saito, Y., Yamashita, D., Kitahara, H., & Kobayashi, Y. (2023). Factors Associated with Impaired Resistive Reserve Ratio and Microvascular Resistance Reserve. Diagnostics, 13(5). https://doi.org/10.3390/diagnostics13050950
100. Yang, Z., Lin, S., Liu, Y., Ren, Q., Ge, Z., Wang, C., Bi, Y., Wang, X., & Mao, J. (2022). Traditional chinese medicine in coronary microvascular disease. In Frontiers in Pharmacology (Vol. 13). Frontiers Media S.A. https://doi.org/10.3389/fphar.2022.929159
101. Yang, Z., Liu, Y., Li, Z., Feng, S., Lin, S., Ge, Z., Fan, Y., Wang, Y., Wang, X., & Mao, J. (2023). Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies. In Biomedicine and Pharmacotherapy (Vol. 164). Elsevier Masson s.r.l. https://doi.org/10.1016/j.biopha.2023.115011
102. Yannopoulos, D., Bartos, J. A., Aufderheide, T. P., Callaway, C. W., Deo, R., Garcia, S., Halperin, H. R., Kern, K. B., Kudenchuk, P. J., Neumar, R. W., & Raveendran, G. (2019). The Evolving Role of the

Cardiac Catheterization Laboratory in the Management of Patients With Out-of-Hospital Cardiac Arrest: A Scientific Statement From the American Heart Association. In Circulation (Vol. 139, Issue 12, pp. e530–e552). NLM (Medline). https://doi.org/10.1161/CIR.0000000000000630

103. Yong, A. S., Layland, J., Fearon, W. F., Ho, M., Shah, M. G., Daniels, D., Whitbourn, R., MacIsaac, A., Kritharides, L., Wilson, A., & Ng, M. K. (2013). Calculation of the index of microcirculatory resistance without coronary wedge pressure measurement in the presence of epicardial stenosis. JACC: Cardiovascular Interventions, 6(1), 53–58. https://doi.org/10.1016/j.jcin.2012.08.019
104. Yousef, M. O., Ahmed, B., Abdelaziz, I., & Mohamed, H. (2016). The Role of Cardiac Catheterization in the Diagnosis and Assessment of Heart Disease in Khartoum. https://www.researchgate.net/publication/296639444
105. Zhang, J., Ma, M., Li, H., Pu, Z., Liu, H., Huang, T., Cheng, H., Gong, Y., Chu, Y., Wang, Z., Jiang, J., & Xia, L. (2023). Early diagnosis of coronary microvascular dysfunction by myocardial contrast stress echocardiography. Mathematical Biosciences and Engineering, 20(5), 7845–7858. https://doi.org/10.3934/mbe.2023339
106. Zuin, M., Q Vu, P., T Vu, L., Mihas, I., Nguyen, T., & Rigatelli, G. (2022). Artificial Intelligence In Coronary Artery Disease: Essential Aspects. TTU Journal of Biomedical Sciences, 1(1), 21–24. https://doi.org/10.53901/tjbs.2022.10.art03